New precision drug targets genetic driver in tough cancers
Disease control
Completed
This study tested a new targeted pill called RLY-4008 in people with advanced cancers, mainly a type of bile duct cancer, that have specific changes in a gene called FGFR2. The main goals were to find a safe dose and see if the drug could shrink tumors. It was for patients whose …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 03:42 UTC